With the growing global opportunities in AI and exosome applications, biotech companies are actively enhancing their strategic alliances to expand their presence in international markets.
ADIMMUNE Corporation is steadily advancing its operations, supported by a doubling of its 2025 European orders and commercialization efforts with Korean partners set to gain traction in the latter half of the year. Notably, its biosimilar for the macular degeneration injection drug Eylea is expected to receive regulatory approvals in Korea by the end of 2024, in Canada by the first quarter of 2025, and in Europe by the second quarter of 2025, enabling market launches in these regions.
BIONET CORP, along with its subsidiaries Genetics Generation Advancement and BIONET Therapeutics, is leveraging its proprietary AI system to analyze miRNA expression levels and identify optimal exosome combinations. Through strategic alliances with medical institutions, aesthetic medicine, cosmetics developers, and medical aesthetics equipment manufacturers, BIONET is accelerating its entry into the regenerative medicine sector. Its Exosome Foundry business model—a global exosome research and manufacturing service—has been actively promoting expansion into overseas markets, including Malaysia, Thailand, Indonesia, and Japan.
Genomics BioSci & Tech Co. (Genomics) has recently engaged in strategic collaborations with domestic and international partners, benefiting from a recovery in demand for gene sequencing and synthesis services, high visibility of orders for LPD products, and ongoing trial production at its GMP nucleic acid facility. Overseas market expansion remains a key focus, with initiatives aligning with Taiwan’s New Southbound Policy. The company has begun establishing a presence in Indonesia, the Philippines, and Australia, with Indonesia as its initial target market, employing a two-pronged strategy to aggressively enter the region.
PURIBLOOD MEDICAL CO. has signed two agreements with the Brazilian Association of Hematology, Hemotherapy, and Cellular Therapy (ABHH) and the major medical distributor Cromo, covering clinical trials and exclusive distribution. These agreements reflect Taiwan's ambition to enter South America’s largest market for hematological products and establish a new milestone in Taiwan-Brazil collaboration in medical and blood research technologies.
AmCad BioMed is set to introduce its AmCAD-UT® thyroid ultrasound analysis system to Geneva University Hospital in Switzerland by the end of 2024. Additionally, it has signed a memorandum of understanding (MOU) with the United Arab Emirates to officially commence business collaborations in the Middle East.
GENERAL BIOLOGICALS has obtained Taiwan TFDA approval for the project-based manufacturing of its GBC CL i120 chemiluminescence immunoassay (CLIA) analyzer. At the same time, the company is advancing its application for EU IVDR medical device certification, opening new opportunities for both domestic and international business.
Resource: 6家生技廠強化策略結盟 擴大搶進海外商機
